logo

WHAT IS T-CELL-BASED IMMUNOTHERAPY?

T cells are immune cells that fight infection. In T-cell immunotherapy, some T cells are removed from a patient’s blood. Then, the cells are changed in a laboratory, so they have specific proteins called receptors. The receptors allow those T cells to recognize the cancer cells. The changed T cells are grown in the laboratory and returned to the patient’s body. Once there, they seek out and destroy cancer cells.

T-Cell-based ImmunotherapiesIndicationReferences
CAR-T (Chimeric Antigen Receptor)

Hematology Malignancies:

  • – Paed & Adult refractory/relapsed B-cell ALL
  • – Non-Hodgkin Lymphomas (NHL)
  • – Diffuse Large B-cell Lymphoma (DLBCL)
  • – Multiple Myelomas; Hodgkin Lymphomas
  • – Anaplastic Large cell Lymphoma
  • – refractory/relapsed Glioblastoma multiforme (Brain)
1-17
TCR-T (T-Cell Receptor)

HPV-associated cancers, such as:

  • – Cervical
  • – Vulvar
  • – Vaginal
  • – Penile
  • – Anal
  • – Oropharyngeal
  • – Larynx, etc.
18-23
TAA-T (Tumor-Associated Antigen)

Variety of advanced cancers, such as pancreatic cancer, bladder cancer, ovarian cancer, etc.

24-27
TIL (Tumor Infiltrating Lymphocytes)

Variety of advanced cancers, such as glioma, colon cancer, breat cancer, colorectal cancer with liver metastases, etc.

28-34
scFv ICI (Short chain fragment Immune checkpoint inhibitors – cells or soluble ICI)

Variety of advanced cancers, such as Non-Small Cell lung Cancer (NSCLC), advanced metastatic breast cancer, etc.

Categories of T-Cell–Based Immuno-Oncology Therapies

PROVEN IMMUNOTHERAPY THAT YOU ACTUALLY CAN HAVE

This decade, a lot of clinical trials regarding CAR-T therapy were carried out around the word. As of April 19, 2018, the information from Clinicaltrails.gov showed that more than 270 CAR-T related studies were undergoing clinical trials in many different countries.

By analyzing the overall response rate (ORR) and complete response rate (CRR) of CAR-T therapy in patients with different tumors, we found that the response rate was significantly higher for patients with hematologic malignancies compared to patients with solid malignancies.